ReviewThe World Allergy Organization journal2018
The global impact of the DRACMA guidelines cow's milk allergy clinical practice.
Review in The World Allergy Organization journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A well-tolerated new amino acid-based formula for cow's milk allergy.Immunity, inflammation and disease · 2020Trial
- Tolerance of Infants Fed a Hydrolyzed Rice Infant Formula with 2'-Fucosyllactose (2'-FL) Human Milk Oligosaccharide (HMO).Nutrients · 2024Article
- Review
- Gut microbiome features in pediatric food allergy: a scoping review.Frontiers in allergy · 2024Article
- Polymorphic Variants of Interleukin-13 R130Q and Interleukin-4 T589C in Children with and without Cow's Milk Allergy.Life (Basel, Switzerland) · 2022Article
- Body growth assessment in children with IgE-mediated cow's milk protein allergy fed with a new amino acid-based formula.Frontiers in allergy · 2022Article
- The potential role of preventive and therapeutic immunonutrition strategies for pediatric food allergy: A mini-review.Frontiers in nutrition · 2022Review
- Clinical Observation of Extensively Hydrolysis Protein Formula With Feeding Intolerance in Preterm Infants.Frontiers in pediatrics · 2022Article
- Effects of enzymatic treatments on the hydrolysis and antigenicity reduction of natural cow milk.Food science & nutrition · 2021Article
- Immunonutrition for Pediatric Patients With Cow's Milk Allergy: How Early Interventions Could Impact Long-Term Outcomes.Frontiers in allergy · 2021Review
- Tolerogenic Effect Elicited by Protein Fraction Derived From Different Formulas for Dietary Treatment of Cow's Milk Allergy in Human Cells.Frontiers in immunology · 2020Article
- Use of Soy-Based Formulas and Cow's Milk Allergy: Lights and Shadows.Frontiers in pediatrics · 2020Review
- Nano-Biosensing Platforms for Detection of Cow's Milk Allergens: An Overview.Sensors (Basel, Switzerland) · 2019Review
- Challenges of managing food allergy in the developing world.The World Allergy Organization journal · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe 2010 Diagnosis and Rationale for Action against Cow's Milk Allergy (DRACMA) guidelines are the only Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines for cow's milk allergy (CMA). They indicate oral food challenge (OFC) as the reference test for diagnosis, and suggest the choice of specific alternative formula in different clinical conditions. Their recommendations are flexible, both in diagnosis and in treatment. OBJECTIVES &
methodsUsing the Scopus citation records, we evaluated the influence of the DRACMA guidelines on milk allergy literature. We also reviewed their impact on successive food allergy and CMA guidelines at national and international level. We describe some economic consequences of their application.
resultsDRACMA are the most cited CMA guidelines, and the second cited guidelines on food allergy. Many subsequent guidelines took stock of DRACMA's metanalyses adapting recommendations to the local context. Some of these chose not to consider OFC as an absolute requirement for the diagnosis of CMA. Studies on their implementation show that in this case, the treatment costs may increase and there is a risk of overdiagnosis. Interestingly, we observed a reduction in the cost of alternative formulas following the publication of the DRACMA guidelines.
conclusionsDRACMA reconciled international differences in the diagnosis and management of CMA. They promoted a cultural debate, improved clinician's knowledge of CMA, improved the quality of diagnosis and care, reduced inappropriate practices, fostered the efficient use of resources, empowered patients, and influenced some public policies. The accruing evidence on diagnosis and treatment of CMA necessitates their update in the near future.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.